Welcome to our dedicated page for OS Therapies Incorporated news (Ticker: OSTX), a resource for investors and traders seeking the latest updates and insights on OS Therapies Incorporated stock.
OSTX (OS Therapies, Inc.) is an innovative biotechnology company committed to developing advanced therapies for the treatment of osteosarcoma, a rare and aggressive bone cancer primarily affecting children and young adults. The company leverages cutting-edge research and technology to create targeted treatments aimed at improving patient outcomes and quality of life.
OSTX's core business involves the development of novel immunotherapies and precision medicine. The company's flagship project, OST-01, is a groundbreaking immunotherapy designed to specifically target and eliminate osteosarcoma cells while sparing healthy tissue. This pioneering approach has shown promising results in preclinical studies and is currently in the early stages of clinical trials.
Recently, OS Therapies has secured significant funding and established strategic partnerships with leading research institutions and pharmaceutical companies. These collaborations are aimed at accelerating the development and commercialization of their therapeutic pipeline.
Financially, OS Therapies, Inc. has demonstrated robust growth and stability. The company's recent funding rounds have attracted major investors, underscoring confidence in OSTX's potential. This financial backing enables OSTX to expand its research efforts and bring its innovative treatments to market more rapidly.
OS Therapies is also actively engaged in several promising projects beyond OST-01. These include exploratory research into other rare cancers and potential applications of their immunotherapy platform. The company's commitment to scientific excellence and patient care continues to drive its mission forward.
Overall, OSTX is a key player in the biotechnology sector, dedicated to transforming the landscape of cancer treatment through innovation and collaboration. For investors and stakeholders, OS Therapies offers a compelling opportunity in the promising field of cancer immunotherapy.
OS Therapies (NYSE American: OSTX) has announced its participation in the H.C. Wainright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York City. The company's President & CEO, Paul Romness, MPH, will deliver a virtual presentation highlighting:
- The company's potentially pivotal fully-enrolled Phase 2b trial of OST-HER2 for preventing resected, recurrent human osteosarcoma
- OST-HER2's pending pivotal safety study in treating canine osteosarcoma
- The company's tunable Antibody Drug Conjugate (tADC) therapeutic platform technology
The virtual presentation will be available starting at 7:00 AM ET on September 9, 2024. Interested parties can register for the conference at https://hcwevents.com/annualconference/.
OS Therapies (NYSE American: OSTX) announced the completion of treatment for the final patient in its Phase 2b clinical trial of OST-HER2 for recurred, resected Osteosarcoma. The trial, AOST-2121 (NCT04974008), enrolled 41 patients across 21 U.S. sites. The primary endpoint is 12-month Event Free Survival, with final evaluation expected in early Q4 2024. OST-HER2 is a Listeria-based immunotherapeutic vaccine designed to prevent metastasis and increase survival in Osteosarcoma patients.
The study aims to demonstrate efficacy in patients with high recurrence risk. Topline data, including 12-month Event Free Survival and interim 2-year Overall Survival, is anticipated in Q4 2024. This trial is significant as no new FDA-approved treatments have improved Osteosarcoma outcomes in over 40 years.
OS Therapies (NYSE American: OSTX) has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. Dr. Shor will assist in selecting antibodies and payloads for the company's tunable ADC platform, which uses proprietary pH-sensitive SiLinker™ silicone linker technology. With 20 years of experience in oncology discovery programs, Dr. Shor brings expertise from roles at Pfizer, Wyeth, and as CEO of Manhattan BioSolutions. His background includes developing small molecule kinase inhibitors, biologics, and nanoparticles. At Pfizer, he led teams developing novel ADCs and supported the BLA filing for Inotuzumab, approved for leukemia treatment in 2017. Dr. Shor's appointment aims to strengthen OS Therapies' ADC development capabilities.
OS Therapies (NYSE American: OSTX), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, has issued a clarification regarding the CUSIP identifier of its common stock. The company's stock began trading on the NYSE American on August 1st, 2024, under CUSIP 68764Y108. On August 5th, due to a pre-listing corporate action, a new CUSIP 68764Y207 was assigned. All shares under the old CUSIP are now identified under the new CUSIP, with no share splits or similar actions occurring between August 1-5, 2024. OS Therapies urges all market participants, especially brokerage firms, to update their records accordingly.
OS Therapies (NYSE American: OSTX), a clinical-stage biopharmaceutical company, has been accepted into Johnson & Johnson Innovation – JLABS. The company aims to develop its tunable Antibody Drug Conjugate (ADC) linker-based platform at JLABS. This platform uses pH sensitive linkers & coating technology to reduce off-target effects, potentially improving safety and increasing the diversity of therapeutic payloads delivered.
OS Therapies' goal is to offer improved efficacy compared to other ADCs in the market or in development. The company's unique linker platform allows for the creation of new intellectual property for both novel and off-patent targeting antibodies and drug payloads. This development could potentially lead to more effective and safer ADC-based therapies in the future.
OS Therapies (NYSE American: OSTX) reported Q2 2024 financial results, highlighting a successful IPO on July 31, 2024, raising $6.4 million without issuing warrants. The company converted all outstanding preferred shares and debt into equity, resulting in 20.85 million common shares outstanding post-IPO. Key points include:
1. Cash runway extended into mid-2025
2. $1.557 million net operating loss in Q2 2024, down from $2.505 million in Q2 2023
3. Net loss per share of $0.26 on 5.991 million weighted average shares
4. Fully enrolled Phase 2b clinical trial for OST-HER2 in osteosarcoma, with results expected in Q4 2024
5. Positive safety data from Phase 1 study of OST-HER2 in breast cancer
RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma on Bloomberg TV on August 10, 2024, at 7 p.m. ET. Paul Romness, Chairman and CEO of OS Therapies, will provide a corporate update on the company's novel treatments for Osteosarcoma and other solid tumors. OS Therapies' product candidates, OST-HER2 and OST-tADC, aim to address gaps in pediatric and young adult cancer care. The company is approaching significant clinical milestones and potential revenue streams, including out-licensing deals and a priority review voucher valued at $100-110M.
OS Therapies (NYSE American:OSTX) has announced its Scientific and Medical Advisory Board (SMAB) for osteosarcoma, consisting of experts from six US institutions. The SMAB will assist in FDA engagement regarding OST-HER2, the company's lead immunotherapy product candidate. OST-HER2, an innovative HER2-targeted Listeria-based immunotherapy, is designed to combat osteosarcoma by triggering immune responses against HER2-expressing cancer cells.
The company has fully enrolled a Phase IIb clinical trial with 41 patients across 21 US sites, reporting positive interim data in June 2024. Topline data is expected in Q4 2024. OST-HER2 has received multiple FDA designations, including Rare Pediatric Disease, Fast Track, and Orphan Drug. OS Therapies is pursuing Breakthrough Therapy Designation and plans to expand into breast cancer treatment post-FDA approval for osteosarcoma.
OS Therapies (NYSE-A: OSTX) has formed a Patient Advocacy Advisory Board (PAAB) for its osteosarcoma program. The PAAB will represent the osteosarcoma community in discussions with the FDA regarding potential Biologics License Authorization for OST-HER2, the company's immunotherapeutic product candidate. The board includes representatives from various osteosarcoma organizations and patients.
OST-HER2 is an innovative immunotherapy using a HER2 bioengineered form of Listeria monocytogenes to trigger an immune response against HER2-expressing cancer cells. A Phase IIb clinical trial for recurred, resected osteosarcoma has been fully enrolled with 41 patients across 21 US sites. Positive interim data was reported in June 2024, with topline data expected in Q4 2024.
OST-HER2 has received Rare Pediatric Disease, Fast Track, and Orphan Drug Designations from the FDA and EMA. OS Therapies is seeking Breakthrough Therapy Designation based on Phase IIb trial data. The company plans to pursue therapeutic development in breast cancer following FDA approval for osteosarcoma.
OS Therapies (NYSE-A: OSTX) has announced the pricing of its initial public offering of 1,600,000 shares at $4.00 per share, raising $6.4 million in gross proceeds. The company plans to use the funds to advance its clinical development of OST-HER2 and OST-tADC, two innovative cancer treatments. OST-HER2, their lead product, is in a Phase IIb trial for osteosarcoma with topline data expected in Q4 2024. It has received Rare Pediatric Disease, Fast Track, and Orphan Drug Designations from the FDA and EMA. OST-tADC is a next-generation Antibody Drug Conjugate platform. Trading under the symbol OSTX on the NYSE American is set to begin on August 1, 2024, with the offering closing on August 2, 2024.
FAQ
What is the current stock price of OS Therapies Incorporated (OSTX)?
What is the market cap of OS Therapies Incorporated (OSTX)?
What does OS Therapies, Inc. specialize in?
What is OSTX's flagship project?
How is OS Therapies funded?
What are some of OS Therapies' recent achievements?
What is the current status of OST-01?
What other projects is OS Therapies working on?
How does OS Therapies contribute to the field of cancer treatment?
Who are OS Therapies' partners?
What is the significance of OS Therapies' work?
Why should investors be interested in OSTX?
